Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Vomiting 4Nausea 3Gastrointestinal Neoplasms 3Colorectal Neoplasms 2Colonic Neoplasms 2Rectal Neoplasms 1Pancreatic Neoplasms 1Lymphoma 1Carcinoma, Hepatocellular 1Bile Duct Neoplasms 1

Interventions

Gemcitabine 40Cisplatin 24Capecitabine 21Fluorouracil 19Oxaliplatin 17Leucovorin 14pembrolizumab 9Irinotecan 8Radiotherapy 7Erlotinib Hydrochloride 7durvalumab 6Sorafenib 4Photochemotherapy 4Magnetic Resonance Spectroscopy 4Carboplatin 4trametinib 3Trastuzumab 3Radiofrequency Ablation 3Long-Term Synaptic Depression 3Interleukin-12 Subunit p35 3Filgrastim 3Drug Therapy 3Dihematoporphyrin Ether 3Dexamethasone 3Cholangiopancreatography, Endoscopic Retrograde 3Chemotherapy, Adjuvant 3trifluridine tipiracil drug combination 2tivozanib 2tislelizumab 2spartalizumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Bile Duct Neoplasms × Aprepitant × Gastrointestinal × Clear all
NCT01534637 2018-08-15

Aprepitant in Preventing Nausea and Vomiting in Patients Undergoing Chemotherapy and Radiation Therapy for Pancreatic Cancer

Wake Forest University Health Sciences

Phase 2 Completed
22 enrolled 9 charts
Gastrointestinal

Bile Duct Neoplasms, Nausea, Pancreatic Neoplasms, Vomiting

Data powered by HemOnc (CC BY 4.0) Colophon âš¡